We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+1.63%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$388M
AUM Growth
+$192M
Cap. Flow
+$219M
Cap. Flow %
56.4%
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$172M
2
DVAX
Dynavax Technologies
DVAX
+$32.8M
3
SLDB icon
Solid Biosciences
SLDB
+$14.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 70.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$158M 40.64%
+7,281,307
New +$172M
DRNA
2
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$105M 27.1%
7,330,237
– –
SLDB icon
3
Solid Biosciences
SLDB
$900M
$40M 10.31%
258,078
+125,448
+95% +$14.2M
REPL icon
4
Replimune Group
REPL
$1.01B
$39.5M 10.16%
2,838,968
– –
DVAX
5
DELISTED
Dynavax Technologies
DVAX
$30.3M 7.79%
+8,452,235
New +$32.8M
MRNS
6
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.77M 2%
1,260,684
– –
APTX
7
DELISTED
Aptinyx Inc. Common Stock
APTX
$7.77M 2%
2,225,092
– –

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q3 2019 Portfolio in Review

As of Q3 2019, Bain Capital Life Sciences Investors held 7 positions worth $388M, up 97% from $197M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Bain Capital Life Sciences Investors deployed $219M of net new capital in Q3 2019, opening 2 new positions and adding to 1 existing holding. Its largest new stake was SpringWorks Therapeutics: 7,281,307 shares worth $158M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 31% a quarter earlier.

  • Bain Capital Life Sciences Investors's largest Q3 2019 buy was SpringWorks Therapeutics: 7,281,307 shares worth $158M.
  • Bain Capital Life Sciences Investors added most to Solid Biosciences in Q3 2019, an estimated $14.2M increase.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 100% of its $388M portfolio in Q3 2019.
  • Bain Capital Life Sciences Investors opened 2 new positions and closed 0 in Q3 2019.
  • Bain Capital Life Sciences Investors's portfolio value rose 97% quarter-over-quarter to $388M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2019, filed 14 Nov 2019.